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ABSTRACT
Introduction: Hypertension in elderly people is
characterised by elevated systolic blood pressure (SBP)
and increased pulse pressure (PP), which indicate large
artery ageing and stiffness. LCZ696, a first-in-class
angiotensin receptor neprilysin inhibitor (ARNI), is being
developed to treat hypertension and heart failure. The
Prospective comparison of Angiotensin Receptor
neprilysin inhibitor with Angiotensin receptor blocker
MEasuring arterial sTiffness in the eldERly
(PARAMETER) study will assess the efficacy of LCZ696
versus olmesartan on aortic stiffness and central aortic
haemodynamics.
Methods and analysis: In this 52-week multicentre
study, patients with hypertension aged ≥60 years with a
mean sitting (ms) SBP ≥150 to <180 and a
PP>60 mm Hg will be randomised to once daily LCZ696
200 mg or olmesartan 20 mg for 4 weeks, followed by a
forced-titration to double the initial doses for the next
8 weeks. At 12–24 weeks, if the BP target has not been
attained (msSBP <140 and ms diastolic BP
<90 mm Hg), amlodipine (2.5–5 mg) and subsequently
hydrochlorothiazide (6.25–25 mg) can be added. The
primary and secondary endpoints are changes from
baseline in central aortic systolic pressure (CASP) and
central aortic PP (CAPP) at week 12, respectively. Other
secondary endpoints are the changes in CASP and CAPP
at week 52. A sample size of 432 randomised patients is
estimated to ensure a power of 90% to assess the
superiority of LCZ696 over olmesartan at week 12 in the
change from baseline of mean CASP, assuming an SD of
19 mm Hg, the difference of 6.5 mm Hg and a 15%
dropout rate. The primary variable will be analysed using
a two-way analysis of covariance.
Ethics and dissemination: The study was initiated in
December 2012 and final results are expected in 2015.
The results of this study will impact the design of future
phase III studies assessing cardiovascular protection.
Clinical trials identifier: EUDract number
2012-002899-14 and ClinicalTrials.gov NCT01692301.
INTRODUCTION
Hypertension accounts for 9.4 million cardio-
vascular (CV) deaths annually worldwide and
is affecting more than two-thirds of people
aged ≥65 years, an age group that is growing
globally.1 2 The treatment of hypertension has
been shown to reduce the risk of morbidity
and mortality associated with elevated blood
pressure (BP), including stroke, ischaemic
heart disease, heart failure, chronic kidney
disease and possibly cognitive decline.3
Despite the availability of multiple drug classes
with different mechanisms of action, hyperten-
sion, especially systolic blood pressure (SBP),
remains inadequately controlled.4–6
The SBP usually increases from childhood
throughout life, while diastolic BP (DBP)
Strengths and limitations of this study
▪ This is a randomised controlled trial of a new
class of drug therapy (angiotensin receptor
neprilysin inhibitor) for hypertension versus a
comparator that blocks only the angiotensin
receptor—this will inform on the added value of
neprilysin inhibition in the context of systolic
hypertension.
▪ The study incorporates a detailed clinical experi-
mental medicine mechanistic study that will
interrogate the actions of this new drug class on
vascular haemodynamics and function.
▪ The study evaluates a novel treatment approach
for a major unmet clinical need, that is, systolic
hypertension.
▪ The study has inadequate statistical power to
assess the impact of the interventions on major
clinical outcomes beyond blood pressure and
vascular haemodynamics and function.
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remains relatively constant or decreases beyond 50–60
years of age. The changing patterns of BP throughout
life reﬂect different pathologies. In the young, hyperten-
sion is predominantly due to an increased DBP and
mean arterial pressure (MAP), as a result of a relative
increase in cardiac output and/or increased peripheral
vascular resistance.7 On the other hand, advancing age,
beyond mid-life, is associated with an increased stiffness
of large elastic arteries, especially the aorta. Arterial stif-
fening adversely affects the characteristic impedance of
the aorta, requiring more cardiac work and raising SBP
as more stroke volume is delivered during systole owing
to the increased pulse wave velocity (PWV). DBP also
decreases due to less elastic recoil leading to reduced
ﬂow, thus increasing pulse pressure (PP) independent of
any changes in MAP. PWV been shown to be an inde-
pendent predictor of CV outcomes, including mortality,8
myocardial infarction (MI),8 stroke,8 atrial ﬁbrillation,9
cognitive decline10 and renal dysfunction,11 and more
speciﬁcally aortic PWV (aPWV), a robust measure of
aortic arterial stiffness, has been shown to predict the
adverse CV outcomes.7
Another consequence of arterial ageing and stiffening
is that the ampliﬁcation of SBP and PP from the aortic
root to the peripheral arteries diminishes. In a healthy
arterial system, central aortic systolic pressure (CASP)
and PP are ampliﬁed as they move towards the periph-
ery, such that the measured brachial systolic pressure is
typically around 10 mm Hg higher than the correspond-
ing aortic root pressure.12 With ageing, this ampliﬁca-
tion is reduced because of the increased PWV and
the increase in the early wave reﬂection resulting in the
measured brachial SBP and PP becoming closer to the
corresponding aortic root pressures. Some studies have
suggested that central pressures may have a closer correl-
ation than peripheral BP with end-organ damage13–15
and CV risk,15 such as extent of coronary atherosclerosis,
carotid intima-media thickness, left ventricular (LV)
hypertrophy and LV diastolic function.14 16 17
These observations raise the intriguing question as to
whether treatments used to lower BP could differentially
affect aortic pressure relative to brachial pressures and
also arterial stiffness per se. It has been demonstrated
that BP-lowering drugs can have marked differential
effects on central aortic pressure (CAP) and brachial
BP.18 These effects mimic a functional antiageing effect
in terms of their impact on wave-form morphology, and
greater reduction in central pressures relative to brachial
pressures. Intriguingly, the β-blockers, a drug class which
was least effective at lowering aortic pressure also
appeared to be the least effective class at reducing the
risk of stroke in elderly patients.18 This supports the
concept that the more effective lowering of aortic rela-
tive to brachial pressure may be clinically important.
Despite the ﬁndings cited above, controlling SBP
remains the most important unmet need in the clinical
management of hypertension. The rise in SBP and PP
with ageing appears to be strongly related to arterial
stiffening and increased impedance to ﬂow through a
stiff aorta. This suggests that the treatments targeting
aortic stiffening and reducing characteristic impedance
would be effective particularly at reducing systolic pres-
sure. Early proof of this concept came from the studies
with omapatrilat, a vasopeptidase inhibitor that simultan-
eously inhibits neprilysin and ACE. Neprilysin inhibition
enhances natriuretic peptide (NP) levels by blocking
their degradation. NP has vasodilating actions, which
could reduce aortic stiffness, improve characteristic
impedance and thereby reduce SBP and PP. Studies with
omapatrilat show greater improvements in aortic charac-
teristic impedance compared with enalapril, beyond the
effects of BP lowering after 12 weeks of therapy.19 This
beneﬁt on aortic function was also associated with
impressive data on SBP and PP lowering in patients with
hypertension.
Although omapatrilat was withdrawn due to safety con-
cerns, a proof of concept was established for concomitant
inhibition of neprilysin and renin-angiotensin-aldosterone
system (RAAS) with the potential to be an attractive
treatment strategy to improve aortic haemodynamics.
Increased NP levels also promote natriuresis and reduce
sympathetic tone, together with antiproliferative and
antihypertrophic effects and inhibition of aldosterone
secretion.20 Alongside, suppression of RAAS would be
complementary to neprilysin inhibition, which attenuates
vasoconstriction, reduces sodium and water retention and
also inhibits the development of CV hypertrophy and
adverse remodelling.
Recently, LCZ696, a ﬁrst-in-class angiotensin receptor
neprilysin inhibitor (ARNI), has been developed.
LCZ696 delivers systemic exposure to a neprilysin inhibi-
tor prodrug, AHU377 (which rapidly converts into active
LBQ657), and an angiotensin receptor blocker (ARB),
valsartan. LCZ696 at 100, 200 and 400 mg once daily, in
patients with mild-to-moderate essential hypertension,
resulted in greater BP reductions than corresponding
doses of valsartan alone (160 and 320 mg) and was well
tolerated.21 LCZ696 compared with valsartan was effect-
ive especially at reducing brachial SBP and PP.
Furthermore, in patients with heart failure with pre-
served ejection fraction, LCZ696 has shown to reduce
N-terminal-pro B-type natriuretic peptide (NT-proBNP),
a biomarker of LV wall stress, to a greater extent than
valsartan alone at 12 weeks and was well tolerated.22
Thus, the big challenge in hypertension treatment is to
reduce the SBP, and the available evidence suggests that
this could be achieved by improving the haemodynamic
performance of the ageing aorta. The Prospective com-
parison of Angiotensin Receptor neprilysin inhibitor with
Angiotensin receptor blocker MEasuring arterial
sTiffness in the eldERly (PARAMETER) study is designed
to compare the effect of LCZ696 with olmesartan, an
ARB, on CASP, other measures of central aortic haemo-
dynamics and arterial stiffness and ambulatory BPs in
elderly patients with an elevated brachial SBP and a
widened PP. The widened PP was chosen as an entry
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criteria as being indicative of aortic stiffening and
advanced aortic ageing. The objective was to determine
whether the ARNI LCZ696 can reverse some of the
effects of arterial ageing in elderly patients with systolic
hypertension, and thereby improve aortic pressures and
haemodynamics. The study was initiated in December
2012 and the ﬁnal results are expected in 2015. This
manuscript describes the design, objectives and prespeci-
ﬁed analysis plan for the PARAMETER study.
METHODS
Study design
The PARAMETER study is a 52-week, multicentre, ran-
domised, double-blind, active-controlled, parallel-group
study, involving 51 centres from 13 countries (Europe
47%, South America 14%, Asia 19% and the USA 20%
—see online supplement for list of local investigators
and participating centres). The study includes a screen-
ing period, a placebo run-in and an initial double-blind
treatment period of 12 weeks with LCZ696 monotherapy,
followed by a double-blind extension of 40 weeks, during
which add-on therapy is allowed to reach the BP treat-
ment goal. Patients will be randomised to receive either
once daily LCZ696 200 mg or olmesartan 20 mg for
4 weeks, followed by a forced titration to double the
initial doses for the next 8 weeks. After 12 weeks,
patients with uncontrolled BP (mean sitting (ms) SBP
>140 and/or msDBP >90 mm Hg) will be prescribed
amlodipine (2.5–5 mg) and then hydrochlorothiazide
(6.25–25 mg) as needed, at an interval of 4 weeks up to
week 24 (ﬁgure 1). This study has been approved by all
relevant ethics committees.
Study participants
Elderly patients (aged ≥60 years) with essential hyper-
tension (either untreated or treated with antihyperten-
sive agents) and patients who have msSBP ≥150 and
<180 mm Hg at randomisation are eligible for inclusion
in the study. Untreated patients (if they are newly diag-
nosed or have not been treated with antihypertensive
drugs for 4 weeks prior to screening) must have msSBP
≥150 and <180 mm Hg at screening and randomisation,
whereas patients who have been treated with antihyper-
tensive agents 4 weeks prior to screening must have
msSBP ≥140 and <180 mm Hg after 1 or 2 weeks of
washout/placebo run-in and ≥150 and <180 mm Hg at
randomisation. All patients must have a PP>60 mm Hg
at randomisation. Patients with malignant or severe
hypertension, secondary causes of hypertension, history
of atrial ﬁbrillation or atrial ﬂutter during the 3 months
prior to screening or active atrial ﬁbrillation or atrial
ﬂutter on ECG, history of CV disease (eg, MI) during
12 months prior to screening and evidence of severe
renal impairment (eg, estimated glomerular ﬁltration
rate <30 mL/min/1.73 m2) are excluded—boxes 1 and
2 summarise the inclusion and exclusion criteria,
respectively. Patients have to provide a written informed
consent before starting any study-related procedures.
The study objectives and endpoints
The primary objective of the study is to demonstrate the
superiority of an LCZ696-based treatment regimen over
an olmesartan-based treatment regimen in reducing
mean CASP after 12 weeks of treatment. Superiority
testing is also planned for the key secondary efﬁcacy
Figure 1 Study design. HCTZ, hydrochlorothiazide; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic
blood pressure.
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assessment, that is, the reduction in mean central aortic
PP (CAPP) after 12 weeks of treatment, and other sec-
ondary efﬁcacy assessments such as mean CASP and
CAPP after 52 weeks of treatment. Mean aPWV, msSBP,
msDBP, msPP, mean ambulatory (ma) BP, maPP and
MAP will also be measured after 12 and 52 weeks of
treatment.
Exploratory assessments comparing the two treatments
after 12 and 52 weeks of treatment include pulse wave
analysis (PWA) variables such as augmentation index
(AIx), augmentation pressure, PP ampliﬁcation ratio,
duration of LV ejection and time to wave reﬂection;
reduction in ma central (mac) BP, macMAP and macPP;
plasma biomarkers including NT-proBNP and urinary
cyclic guanosine monophosphate/creatinine ratio and
other biomarkers related to hypertension.
Haemodynamic measurements
The SphygmoCor X-CEL System (AtCor Medical,
Sydney, Australia) is being used to non-invasively derive
the ascending aortic pressure waveform from the bra-
chial waveform using a validated generalised transfer
function (GTF).23 A properly sized BP cuff is linked to a
computer and software and the CASP, CAPP, augmenta-
tion pressure and AIx are determined from the analysis
of the waveform by the system software.
The SphygmoCor X-CEL system also measures the
carotid-femoral aPWV, the speed of the arterial pressure
waveform as it travels through the descending aorta to
the femoral artery, which is detected from simultan-
eously measured carotid and femoral arterial pulses.
The carotid pulse is detected by applanation tonometry
using a high-ﬁdelity pressure transducer (Millar
Instruments, Houston, Texas, USA), while the femoral
pulse is detected using a partially inﬂated BP cuff
wrapped around the upper thigh. The distance travelled
by the pulse wave is captured by making physical mea-
surements on the body surface according to the manu-
facturer’s recommendations. This new brachial
cuff-based device with an individualised subdiastolic cuff
pressure has recently been validated against the
SphygmoCor device (AtCor Medical) using the classical
radial tonometry-based methodology, and provides an
operator-independent method to assess systolic pressure
and aortic waveforms comparable with the existing vali-
dated tonometric-based methods.24 Measurements using
the SphygmoCor X-CEL system will be performed at
baseline, randomisation, week 12 or at the time of early
discontinuation prior to week 12, week 52 or at the time
of early discontinuation between weeks 12 and 52.
The 24 h maCAP and maPWA will be monitored using
the oscillometric device, Mobil-O-Graph (IEM, Stolberg,
Germany) with integrated ARC solver algorithms
(Austrian Institute of Technology, Vienna, Austria). The
traditional Mobil-O-Graph ambulatory BP monitoring
device has been available for more than a decade and
through several product generations.25–28 The actual BP
measuring unit was validated according to the British
Hypertension Society (BHS) and the European Society of
Hypertension (ESH) recommendations.25 27 The method,
equipped with a GTF to derive aortic pressure waveforms29
is based on brachial readings acquired in the course of the
conventional pressure measurement at the diastolic level.
During the signal acquisition procedure, the received
raw signals are separated into single waves and checked
for their plausibility by means of extreme values and the
corresponding wavelengths using a cross-correlation
Box 1 Inclusion criteria
▸ Patients with essential hypertension aged ≥60 years.
▸ Either untreated or treated with antihypertensive agents, and
who have mean sitting systolic blood pressure (msSBP) ≥150
and <180 mm Hg at randomisation are eligible to be included.
– Untreated patients (if they are newly diagnosed or have not
been treated with antihypertensive drugs for 4 weeks prior
to screening) must have msSBP ≥150 and <180 mm Hg at
screening and randomisation.
– Patients who have been treated with antihypertensive drugs
during 4 weeks prior to screening must have msSBP ≥140
and <180 mm Hg after 1 or 2 weeks of washout/placebo
run-in and ≥150 and <180 mm Hg at randomisation.
– Patients must have a difference in msSBP of within
±15 mm Hg between randomisation and the visit preceding
randomisation.
▸ All patients must have a pulse pressure >60 mm Hg at
randomisation.
▸ Patients who comply with all study requirements and demon-
strate good medication compliance (≥80% compliance rate)
during the single blind placebo run-in period.
Box 2 Exclusion criteria
▸ Malignant or severe hypertension or secondary causes of
hypertension.
▸ History of atrial fibrillation during 3 months prior to screening
or active atrial fibrillation or atrial flutter on ECG during
12 months prior to screening.
▸ History of cardiovascular disease (eg, myocardial infarction)
during 12 months prior to screening.
▸ Existing angina pectoris requiring pharmacological therapy.
▸ Type 1 or 2 diabetes mellitus not well controlled based on the
investigator’s clinical judgement.
▸ Previous or current diagnosis of heart failure (NYHA Class
II-IV), cardiac abnormalities such as second-degree or third-
degree atrioventricular block without a pacemaker, or
malignancy.
▸ Evidence of severe renal impairment (eg, estimated glomerular
filtration rate <30 mL/min/1.73 m2).
▸ Laboratory abnormalities such as serum potassium
>5.5 mmol/L.
▸ Known active liver disease or cirrhosis or evidence of hepatic
disease.
▸ Patients requiring any drug treatment that could affect blood
pressure.
▸ Women of childbearing potential unless using highly effective
methods of contraception during dosing.
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approach. Poor waveforms are removed from further
processing. After applying the GTF to each waveform,
the procedure is repeated. After ﬁnal coherence veriﬁca-
tion, the quality judgement of grade ‘1’ states that at
least 80% of the waveforms were found to be eligible for
further processing, while grades ‘2’ and ‘3’ represent a
≥50% and <50% valid waveforms, respectively.30
Surrogates derived by this technique have been
validated against solid-state catheter measurements and/
or compared with non-invasive readings (eg, tonometry
and echocardiography) for aortic pressures,30–33 wave
reﬂections34 or aPWV.35 36 However, potential clinical use-
fulness has been demonstrated recently.37–39 Furthermore,
feasibility36 and reproducibility40 of cuff-based maPWA
measurements have been reported. The Mobil-O-Graph
maPWA monitor with integrated ARC solver algorithms
holds approvals from CE, FDA and JPAL (among others).
Safety assessments
Safety and tolerability assessments include regular moni-
toring and recording of all adverse events and concomi-
tant medications or signiﬁcant non-drug therapies.
Evaluations of routine blood chemistries, blood counts
with white cell differential and urine analyses, physical
examinations, ECGs and monitoring of vital signs will be
performed at regular intervals.
Statistical analysis plan
A sample size of 183 completers per group is targeted,
which is calculated based on the primary efﬁcacy vari-
able, change from baseline in mean CASP at 12 weeks,
assuming an SD of 19 mm Hg. The sample size is calcu-
lated to ensure a power of 90% to detect statistical sig-
niﬁcance for the comparison of LCZ696-based
treatment regimen with the olmesartan-based treatment
regimen in assessing the superiority at the week 12 end-
point, under the alternative hypothesis that the treat-
ment difference is 6.5 mm Hg at a two-sided signiﬁcance
level of 0.05. Assuming a 15% dropout rate, the total tar-
geted sample size to be randomised is 432 patients (216
per group). The primary variable at the week 12 end-
point will be analysed using a two-way analysis of covari-
ance (ANCOVA), with treatment and region as factors
and the baseline as a covariate. Mean CAPP at the week
12 endpoint will be analysed using the same type of
ANCOVA model used for the primary efﬁcacy analysis.
DISCUSSION
Hypertension in patients over 60 years is often difﬁcult to
control because of age-associated adverse changes in vas-
cular structure and function, especially arterial stiffening
and the resulting changes in aortic haemodynamics. The
majority of elderly patients present with features of arter-
ial stiffening, notably isolated systolic hypertension (ISH),
disrupted circadian BP variation, a non-dipping or early
morning riser phenotype of hypertension and orthostatic
hypertension. Moreover, compared with younger people,
elderly patients are usually characterised with augmented
aortic systolic and PP relative to brachial pressure, asso-
ciated with diminished aortic-brachial pressure ampliﬁca-
tion resulting in the ‘true’ elevation of brachial systolic
and PPs. In turn, the elevated aortic and brachial PPs that
result from increased cardiac work to overcome the
increased characteristic impedance of the aorta due to its
age-related stiffening cause an increased predisposition
to LV hypertrophy, myocardial ischaemia and heart
failure.
Our hypothesis is that the ARNI LCZ696 provides a
novel approach to neurohormonal modulation by con-
comitantly enhancing the NP system and suppressing
the RAAS. Owing to the effects of enhanced NPs and
RAAS inhibition, LCZ696 is anticipated to improve
aortic stiffness, reduce characteristic impedance and
improve central haemodynamics. NPs inhibit the pro-
duction and action of vasoconstrictor peptides, inhibit
sympathetic outﬂow and protect against excess salt and
water retention.41 NPs also inhibit cardiac growth or the
development of compensatory cardiac hypertrophy and
regulate CV function.41 Inhibition of sympathetic tone
might be beneﬁcial in controlling morning surge in BP
in elderly patients with hypertension.42 43 In addition,
suppressing the RAAS offers the potential for many
similar actions on CV structure and function as well as
favourable effects on microcirculatory haemodynamics
as evidenced by observations of reduced albuminuria
and renal protection beyond what might have been
anticipated from BP reduction alone.
It has already been demonstrated that LCZ696 pro-
vides superior reductions in msSBP and msDBP versus
valsartan in an 8-week study including 1328 patients with
mild-to-moderate hypertension. In addition, LCZ696 sig-
niﬁcantly reduced maSBP versus valsartan (between-
treatment difference: LCZ696 200 mg vs valsartan
160 mg, −3.23 mm Hg, 95% CI −5.70 to −0.75; LCZ696
400 mg vs valsartan 320 mg,−5.14 mm Hg, 95% CI −7.70
to −2.59). However, there was no signiﬁcant treatment
difference in maDBP reductions, thereby providing evi-
dence of improvements in PP with LCZ696 versus valsar-
tan. These ﬁndings are consistent with improvements in
large artery function. Furthermore, BP control rates
were signiﬁcantly higher with LCZ696 200 mg than with
160 mg valsartan (46% (78/168) vs 33% (54/163),
p=0·0147). Importantly, in these studies, unlike the vaso-
peptidase inhibitor omapatrilat, LCZ696 was generally
well tolerated without an incidence of angio-oedema
during 8 weeks of treatment.21
The reported improvements in PP suggest the poten-
tial for LCZ696 to protect more effectively than the exist-
ing BP-lowering agents from several consequences of
ISH and vascular stiffness, such as stroke and diastolic
heart failure. However, in the study by Ruilope et al21
CAP, central haemodynamics and arterial stiffness were
not assessed, precluding a meticulous assessment of the
mechanisms underpinning the superior antihypertensive
properties of LCZ696.
Williams B, Cockcroft JR, Kario K, et al. BMJ Open 2014;4:e004254. doi:10.1136/bmjopen-2013-004254 5
Open Access
In the PARAMETER study, the measurement of CAP
should more accurately assess the loading conditions on
the LV, myocardium, coronary arteries and cerebral vas-
culature, and therefore, theoretically, CAP should
provide a basis for more effective protection against CV
target organ damage and events compared with brachial
pressures. In this regard, even in normotensive indivi-
duals, measurement of aortic BP enhances the ability to
predict the target organ changes.44
The PARAMETER study was initiated in December
2012, with a novel design to evaluate central haemo-
dynamics in elderly patients with ISH and a widened PP
at 12 and 52 weeks of treatment with LCZ696 or ARB
olmesartan. If the changes in CASP at 12 weeks (acute
haemodynamic effect) are larger than that in SBP, this
would support the hypothesis that LCZ696 has the
potential to favourably impact aortic haemodynamics
and improve ventricular-vascular coupling in elderly
patients with aged aortas and ISH. Treatment differences
in PWV at 52 weeks would further support a direct bene-
ﬁcial effect of LCZ696 on aortic stiffness due to struc-
tural changes, independent of MAP, as both treatment
groups will be titrated to achieve similar BP control. The
overall effect of LCZ696 on maBP (maSBP, maDBP and
maPP), 24 h BP variability (SD, covariance) and circa-
dian BP rhythms (nocturnal dipping status and morning
surge) will also be assessed in comparison with olmesar-
tan. The study targets randomisation of 432 patients and
ﬁnal results are expected in 2015. We acknowledge the
limitations of this study which is designed to look at sur-
rogate markers rather than major CV outcomes; never-
theless, this is important to establish whether there are
differential effects of drugs therapies on surrogate out-
comes of CV disease to justify and impact on the design
of subsequent phase III studies assessing the potential of
LCZ696 for enhanced CV disease and stroke prevention
in elderly patients with ISH.
In addition to the PARAMETER study, the efﬁcacy and
safety of LCZ696 are being evaluated in related studies,
for example, in comparison with olmesartan in elderly
patients with mild-to-moderate hypertension, in patients
with systolic hypertension and in patients with systolic
hypertension who did not respond to olmesartan.
Although it is hypothesised in the PARAMETER study
that LCZ696 will be more effective at lowering central
aortic and brachial BP compared with olmesartan, it is
also recognised that other agents may need to be added
to reach recommended BP goals in the elderly patients
with systolic hypertension. Calcium channel blockers
(CCBs, usually amlodipine) and diuretics are the most
commonly used antihypertensive agents in combination
with RAAS blockade for patients failing to achieve their
BP goal with RAAS blockade monotherapy. Besides
being very effective, such combination therapies of spe-
ciﬁc antihypertensive classes may also improve safety and
tolerability. For example, addition of ARBs to CCBs has
been shown to reduce the peripheral oedema associated
with amlodipine monotherapy.45 Similarly, diuretic-
induced hypokalaemia has been shown to be attenuated
when RAAS blockade is combined with diuretic
therapy.46 To further evaluate such combination therap-
ies with LCZ696, the BP-lowering efﬁcacy, safety and tol-
erability are being evaluated in combination with
amlodipine in patients with mild-to-moderate hyperten-
sion, who were non-responsive to amlodipine, and in
patients with systolic hypertension. There are also other
trials investigating the efﬁcacy and safety of LCZ696 in
patients with severe hypertension and in patients with
renal impairment.
In summary, the PARAMETER study will evaluate
mechanisms associated with BP lowering in elderly
patients with an aged CV system as evidenced by systolic
hypertension and a widened PP. The study will deﬁne
whether LCZ696, a ﬁrst-in-class ARNI, is more effective in
lowering CASP and CAPP than ARB olmesartan and also
explore whether this effect is related to a BP-independent
reduction in arterial stiffening, suggesting a novel mechan-
ism to target systolic hypertension, a major and increas-
ingly important unmet therapeutic need in the
management of hypertension in elderly patients.
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